CADM1 Antibody #30994
- WB
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 100 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
CADM1 Antibody recognizes endogenous levels of total CADM1 protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CADM1 protein. Antibodies are purified by peptide affinity chromatography.
Background
CADM1 (cell adhesion molecule 1, TSLC1, Necl-2, IgSF4, SynCAM1) is a member of the immunoglobulin (Ig) cell adhesion superfamily (1). It is a transmembrane protein that is primarily involved in mediating cell–cell adhesion (2,3). CADM1 is comprised of three extracellular Ig-like loops, a transmembrane domain, and a cytoplasmic tail that contains a 4.1 binding motif and a PDZ binding motif. The Ig-like loops contribute to cell-cell junction formation, whereas the cytoplasmic motifs provide structural linkage to the actin cytoskeleton and related adaptor proteins, including actin binding protein 4.1B and membrane-associated guanylate kinases (MAGUKs) (3-5). As an adhesion protein, CADM1 is involved in various biological processes in diverse cells and tissues (6). CADMI functions include structural maintenance and remodeling of epithelium, assembly of neuronal synapses, nerve-mast cell interaction, mast cell behavior, and T cell activation (3,7-9). In many solid tumors, CADM1 has been shown to function as a tumor suppressor by inhibiting malignant proliferation, invasion, and metastasis, while promoting tumor cell apoptosis. In some cases, however, CADM1 has been reported to promote tumor progression (6,10).
- Pietri, T. et al. (2008) Dev Dyn 237, 233-46.
- Murakami, Y. (2005) Cancer Sci 96, 543-52.
- Sakurai-Yageta, M. et al. (2009) Biochem Biophys Res Commun 390, 977-82.
- Murakami, S. et al. (2014) PLoS One 9, e82894.
- Yageta, M. et al. (2002) Cancer Res 62, 5129-33.
- Sawada, Y. et al. (2020) Int J Mol Sci 21, 9732. doi: 10.3390/ijms21249732.
- Fogel, A.I. et al. (2011) EMBO J 30, 4728-38.
- Magadmi, R. et al. (2019) Front Cell Neurosci 13, 262.
- Kim, H.R. et al. (2011) J Exp Med 208, 2545-60.
- Li, H. et al. (2021) Front Cell Dev Biol 9, 714298.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.